(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
05 May 2022 (05.05.2022)

WIPO | PCT

(10) International Publication Number
WO 2022/094122 A1

(51) International Patent Classification:
C07D 209/52 (2006.01) *C07D 403/04* (2006.01)
C07D 401/14 (2006.01)

(21) International Application Number:
PCT/US2021/057106

(22) International Filing Date:
28 October 2021 (28.10.2021)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/106,811 28 October 2020 (28.10.2020) US

(71) Applicant: **VIRACTA SUBSIDIARY, INC.** [US/US]; 2533 S. Coast Hwy 101, Suite 210, Cardiff, California 92007 (US).

(72) Inventors: **DENG, Xiaohu**; 2533 S. Coast Hwy 101, Suite 210, Cardiff, California 92007 (US). **MAI, Wanping**; 2533 S. Coast Hwy 101, Suite 210, Cardiff, California 92007 (US). **MCRAE, Robert C.**; 2533 S. Coast Hwy 101, Suite 210, Cardiff, California 92007 (US).

(74) Agent: **MARGULIEUX, Grant W.**; Wilson Sonsini, 650 Page Mill Road, Palo Alto, California 94304 (US).


(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,

WO 2022/094122 A1

(54) Title: HDAC INHIBITOR SOLID STATE FORMS

Fig 1 XRPD of crystalline Mesylate Form 1 salt



(57) Abstract: The present disclosure relates to the crystalline mesylate Form 1 salt of N-hydroxy 2-{6-[(6-fluoro-quinolin-2-ylmethyl)-amino]-3-aza-bicyclo[3.1.0]hex-3-yl}pyrimidine-5-carboxamide and methods of making the same. The crystalline mesylate Form 1 salt of N-hydroxy 2-{6-[(6-fluoro-quinolin-2-ylmethyl)-amino]-3-aza-bicyclo[3.1.0]hex-3-yl}pyrimidine-5-carboxamide is useful in preparation of pharmaceutical compositions and dosage forms for the treatment of cancer, immune disorders and inflammation.

[Continued on next page]

TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

Published:

— *with international search report (Art. 21(3))*